Author | Year | No. of patient | Drug | PSA RR ≥ 50% | Tumor response rate% | Median PFS, mo | Median OS, mo |
de Bono | 2010 | 378 | Cabazitaxel (TROPIC) | 39.2 | 14.4 | 2.8 | 15.1 |
Fizazi | 2012 | 797 | Abiraterone acetate (COU-AA-301) | 29.5 | 14.8 | 5.6 | 15.8 |
Scher | 2012 | 800 | Enzalutamide (AFFIRM) | 54 | 29 | 8.3 | 18.4 |
Ross | 2007 | 34 | Docetaxel and carbopolatin | 18 | N/A | 3 | 12.4 |
Loriot | 2009 | 40 | Etoposide, carboplatine with or without EMP | 23 | N/A | N/A | 19 |
Sella | 2009 | 15 | Paclitaxel, estramustine, and carboplatin | 60 | 40 | 4 | 14.6 |
Nozawa | 2015 | 44 | Cabazitaxel (Japanese phase I) | 29.5 | 16.7 | 3.68 | N/A |
Current study | 19 | Docetaxel, estramustine phosphate and carbopolatin | 31.6 | 10 | 3.7 | 18 |